Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)
NCT05444348 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 920
Last updated 2025-07-29
Summary
Patients diagnosed with hematologic cancer are at substantial risk of dying, as 5-year survival among patients with acute myeloid leukemia is 20 % and only every second patient treated for incurable myeloma lives 5 years after date of diagnosis. Nevertheless, many overestimate their prognosis, and value of therapy. Patients with hematological cancers frequently have poor end of life outcomes, such as high treatment activity close to death, where clinical effects are doubtful, and low utilization of palliative care. Prognostic awareness and end of life (EOL) issues have urgency in the communication between patients, their caregiving relatives, and clinicians, in order to avoid futile treatments and suffering at EOL. Inspired by advanced care planning, the investigators developed the concept "Advance Consultations Concerning participants Life and Treatment" (ACT) in collaboration with a group consisting of hematologists, nurses, patients, and caregivers. The ACT concept consists of an 8-hour training day for clinicians, clinical tools, system changes, and preparation material for patients and caregivers prior to the consultation. ACT involves patients and caregivers earlier in preparation for life with chronic progressive disease and EOL-decisions, through an intervention based on compassionate communication and early planning of EOL-care. The aim of the study is to investigate the effect of the intervention on use of chemotherapy and quality of EOL-care in patients with hematological malignancy. Based on the results of the completed pilot study, the investigators are planning a nationwide 2-arm cluster randomized controlled trial where 40 physicians and 80 nurses across seven different hematological departments are randomized to either usual care or ACT training and completing ACT conversations. The investigators expect to include a total of 400 patients and their family caregivers. It is hypothesized that the ACT intervention will decrease use of futile chemotherapy, prepare patients and caregivers for difficult end-of-life-decisions, and improve quality of end-of-life care in hematology.
Conditions
Interventions
- BEHAVIORAL
-
Advance consultation concerning your life and treatment (ACT )
The ACT intervention consists of: an 8 h training day for clinicians including clinical materials such as a conversation aid and conversations guide. 6o minutes ACT-intervention sessions in daily clinic. the patients and caregivers will receive preparatory material prior for the ACT-intervention sessions, and a 30 min follow-up telephone call from the nurse within one week after the ACT-session. Clinicians will receive five sessions of followup supervision within the 24 months of intervention. The 60 min ACT-intervention session is an interdisciplinary conversation with nurse, physician, patient, and caregiver discussing issues of importance of patient and caregiver. The issues are based on the preparatory material focusing on information level and prognosis, patient's and caregiver's values, hopes, fears and worries regarding the future care with progressive disease.
Sponsors & Collaborators
-
Rigshospitalet, Denmark
collaborator OTHER -
Zealand University Hospital
collaborator OTHER -
Odense University Hospital
collaborator OTHER -
Vejle Hospital
collaborator OTHER -
Esbjerg Hospital - University Hospital of Southern Denmark
collaborator OTHER -
Gødstrup Hospital
collaborator OTHER -
Aarhus University Hospital
collaborator OTHER -
Aalborg University Hospital
collaborator OTHER -
Christoffer Johansen
lead OTHER
Principal Investigators
-
Christoffer Johansen, Professor · Rigshospitalet, Denmark
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-08-01
- Primary Completion
- 2026-10-01
- Completion
- 2026-10-01
Countries
- Denmark
Study Locations
More Related Trials
-
Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS
NCT04482894 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Multidisciplinary Follow-up of Patients Treated for Malignant Hematological Disease
NCT03031106 ·Status: UNKNOWN
-
Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML
NCT02461537 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Gelonin Purging of Autologous Stem Cells for Transplantation
NCT00043810 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Feasibility of Telehealth Palliative Care and Digital Symptom Monitoring for Patients With Acute Myeloid Leukemia
NCT04885127 ·Status: COMPLETED ·Phase: NA
-
A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy
NCT03310918 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Treatment of Adult ALL With an MRD-directed Programme.
NCT00358072 ·Status: COMPLETED ·Phase: PHASE2
-
Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT00459524 ·Status: COMPLETED
-
Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years
NCT01828489 ·Status: UNKNOWN ·Phase: PHASE3
-
Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT00844441 ·Status: COMPLETED ·Phase: NA
-
All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00151255 ·Status: COMPLETED ·Phase: PHASE3
-
Outcomes of Acute Myeloid Leukemia Patients
NCT04392310 ·Status: UNKNOWN
-
Effect of Chemotherapy vs No Chemotherapy Pre-transplant to MDS Undergoing Allo-HSCT
NCT02850822 ·Status: UNKNOWN
-
A Phase II Study on Allogeneic Stem Cell Transplantation in Patients With Active Acute Leukemia
NCT01814488 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide
NCT00125606 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia
NCT04415008 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Quality of Life-Guided Transfusion in Refractory MDS or AML
NCT07328191 ·Status: RECRUITING ·Phase: NA
-
A Telehealth Advance Care Planning Intervention for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
NCT04745676 ·Status: COMPLETED ·Phase: NA
-
ObServatory Children Acute RElated Therapy Leukemia
NCT04450784 ·Status: UNKNOWN
-
Medium Dose of Cytarabine and Mitoxantrone
NCT04024241 ·Status: UNKNOWN
-
Study of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine Hospital
NCT05558943 ·Status: NOT_YET_RECRUITING
-
A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous Leukemia
NCT00400673 ·Status: COMPLETED ·Phase: PHASE2
-
An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies
NCT05433090 ·Status: COMPLETED ·Phase: NA
-
Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia
NCT00342316 ·Status: COMPLETED ·Phase: NA
-
Health Care Utilisation Among Survivors of Childhood Acute Lymphoblastic Leukaemia
NCT03985826 ·Status: COMPLETED